Mankind Pharma Gains 1.05%: 2 Key Factors Driving the Week’s Movement

27 January: Stock Hits 52-Week Low Amid Market Pressures

On 27 January 2026, Mankind Pharma Ltd’s share price declined to a fresh 52-week low of Rs.2,060, closing at Rs.2,094.25, down 0.40% for the day. This decline followed two consecutive days of losses, with the stock falling 2.58% over that period. The intraday low of Rs.2,060 represented a 2.03% drop from the previous close, signalling sustained downward momentum.

The broader market environment was relatively positive, with the Sensex closing at 35,786.84, up 0.50%. However, the stock underperformed the benchmark, reflecting company-specific challenges. Mankind Pharma’s share price traded below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish technical stance.

Financially, the company has faced headwinds with a 20.05% decline in profit after tax over the latest six months and a significant 122.24% increase in interest expenses for the nine months ended September 2025. The return on capital employed (ROCE) stood at a modest 12.33% for the half year, contributing to a downgrade in the Mojo Grade to Sell with a score of 38.0 as of November 2025.

28 January: Surge in Derivatives Open Interest Signals Market Activity

Following the 52-week low, Mankind Pharma saw a notable 10.75% increase in open interest in its derivatives segment on 28 January, rising from 10,047 to 11,127 contracts. This surge was accompanied by a futures volume of 4,972 contracts and a futures value of approximately ₹10,077.5 lakhs. The options segment held a significantly larger notional value of ₹1,395.3 crores, highlighting active participation in the derivatives market.

Despite this heightened activity, the stock price showed only a modest recovery, closing at Rs.2,115.60, up 1.02% on the day and 2.16% above its 52-week low. This gain outperformed the Pharmaceuticals & Biotechnology sector’s 0.32% and the Sensex’s 0.28% returns on the same day, suggesting some positive investor positioning.

However, the stock remained below all key moving averages, maintaining a bearish medium- to long-term technical outlook. Delivery volumes declined by 5.32% compared to the five-day average, indicating cautious sentiment among long-term holders. The increase in open interest alongside rising volume suggests fresh capital entering the market, possibly reflecting speculative bets or hedging strategies amid uncertain fundamentals.

29-30 January: Mixed Price Movements Amid Market Stability

On 29 January, Mankind Pharma’s stock price slipped 0.64% to Rs.2,102.15, despite the Sensex gaining 0.22%. The decline was accompanied by low volume, reflecting subdued investor interest. However, on 30 January, the stock rebounded by 1.08% to close at Rs.2,124.90, marking the week’s highest close and a 1.05% gain from the previous Friday’s close of Rs.2,102.75.

The Sensex closed slightly lower on 30 January, down 0.22%, indicating that Mankind Pharma outperformed the benchmark on the final trading day. This modest recovery was supported by increased volume and the prior day’s derivatives activity, though the stock remains below all major moving averages, signalling that the medium-term downtrend has yet to be decisively broken.

Key Takeaways

Positive Signals: Despite hitting a 52-week low early in the week, Mankind Pharma demonstrated resilience with a 1.05% weekly gain, supported by increased derivatives market activity and a modest price rebound. The surge in open interest and futures volume on 28 January indicates active market participation and potential positioning for volatility or directional moves.

Cautionary Factors: The stock remains below all major moving averages, reflecting a bearish medium- to long-term technical outlook. Financial metrics such as declining profit after tax, rising interest expenses, and a modest ROCE contribute to a cautious fundamental backdrop. The Mojo Grade downgrade to Sell and a low Mojo Score of 38.0 further underline the subdued sentiment. Delivery volumes have declined, suggesting waning conviction among long-term holders.

Market Context: The Sensex outperformed Mankind Pharma over the week, rising 1.62% compared to the stock’s 1.05% gain. The Pharmaceuticals & Biotechnology sector showed modest gains, with Mankind Pharma slightly outperforming its sector on 28 January but underperforming on other days. The stock’s large market capitalisation and liquidity support active trading but also imply limited upside from a market cap perspective.

Conclusion

Mankind Pharma Ltd’s week was characterised by a challenging start with a fresh 52-week low, followed by a tentative recovery supported by increased derivatives activity and modest price gains. While the stock managed to close the week higher by 1.05%, it lagged behind the broader Sensex’s 1.62% rise. The persistent trading below key moving averages and deteriorating financial fundamentals maintain a cautious outlook. The surge in open interest suggests market participants are positioning for potential volatility, but the absence of a clear technical breakout or fundamental improvement means the stock remains under pressure. Investors and traders should monitor volume trends and price action closely for signs of a sustained reversal before adjusting their positions.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →